Insights Across the
Access Ecosystem

Real-world evidence has long relied on administrative claims datasets. But claims show utilization, not always clinical reasoning. Here’s why pharmaceutical organizations are increasingly adopting EMR-first evidence models to understand treatment decisions, access dynamics, and real-world care.

The first 90 days after launch reveal whether access strategy is performing in clinical reality. Claims data alone shows utilization — not intent. Here’s why EMR-first evidence is becoming essential for decision-grade post-launch validation across pharmaceutical organizations.

“Standard of care” sounds straightforward — but treatment patterns vary widely across payers, geographies, and health systems. When comparator assumptions don’t reflect real-world practice, value arguments can lose credibility. Here’s why comparator strategy deserves closer scrutiny.

Winning coverage doesn’t guarantee adoption. Access friction, from benefit design to provider workflow, can quietly undermine uptake after launch. Here’s how leading teams map and address breakdown points before performance drifts.

Winning coverage doesn’t guarantee real-world uptake. Many access strategies break after launch, when early signals fail to predict how products perform in practice. Here’s why coverage alone isn’t enough — and where teams should be looking next.

Contracting rarely follows the original script. As payer assumptions shift mid-negotiation, access teams need real-time insight to adapt quickly and protect leverage. Here’s how leading teams stay ahead.

As contracting season ramps up, payers are testing subscription pilots, outcomes triggers, and hybrid models alongside traditional rebates. Here’s what’s emerging — and how manufacturers should prepare.

Insight alone no longer drives access success. Learn how leading organizations activate insight across HEOR, Medical, and Commercial to move faster, stay aligned, and support real-world decision-making.

As payer expectations, policy, and pricing dynamics continue to shift, static access plans are falling short. Learn how scenario thinking and simulation help market access teams prepare for uncertainty, and lead with confidence.

Payers are raising the bar on evidence in 2026, demanding endpoints, real-world outcomes, comparators, and credibility that support real coverage decisions. This blog explores what payers will expect in the year ahead—and how HEOR and access teams can reset their evidence strategies to stay ahead.

Quarterly planning cycles can’t keep pace with the rapid shifts expected in 2026. Learn why static launch plans are no longer enough—and how continuous payer insight, real-time modeling, and cross-functional activation are becoming essential for modern market access strategy.

Payers are signaling exactly how they’ll evaluate price, value, evidence, and contracting in 2026. Based on real-time MAVA® panel insights, this blog outlines the expectations shaping next year’s access environment—and how manufacturers can prepare with clearer evidence, scenario-based contracting, and continuous payer engagement.

2026 will bring major shifts in pricing, contracting, evidence expectations, and payer engagement. Learn what access leaders expect from the year ahead—from IRA pressures to AI-driven contracting—and how forward-looking teams are turning uncertainty into strategic advantage with predictive analytics and continuous payer insight.

HEOR teams are shifting from retrospective analysis to predictive modeling as payers demand forward-looking evidence. Learn how AI-driven forecasting, scenario simulation, and real-time EMR + claims insights are reshaping value storytelling—and why predictive HEOR is becoming the new competitive advantage in market access.